RZRupeng Zhang

Rupeng Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rupeng Zhang has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Han Liang

    Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin’s Clinical Research Center for Cancer

    4 shared publications
  • Jingyu Deng

    Tianjin Medical University Cancer Institute and Hospital

    4 shared publications
  • Fenglin Cai

    Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, The First Clinical Medical College of Nanjing Medical University, Nanjing Medical University, Nanjing, China

    3 shared publications
  • Gang Ma

    Department of Gastric Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin, 300060, China.

    2 shared publications
  • Mengmeng Zhang

    Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China

    2 shared publications
  • Pengliang Wang

    Department of Gastrointestinal Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China

    2 shared publications

Latest Publications

  • LAMB3 drives gastric cancer progression through SAMD4A-mediated degradation of PHLPP2 mRNA leading to sustained PI3K-Akt activation

    by Jiamei Guo, Fenglin Cai, Mengmeng Zhang, Xinyang Nie, Mingzhi Cai, Feiyu Meng, Xingyu Li, Zixiang Wei, Yi Yang, Rupeng Zhang, et al.

    Background Laminin subunit beta 3 (LAMB3) overexpression has been implicated in cancer progression, but its molecular role in gastric cancer (GC) remains unclear. This study aimed to elucidate how LAMB3 promotes GC malignancy and identify the underlying signalling pathways. Methods The clinical significance of LAMB3 was analysed by bioinformatics and immunohistochemistry (IHC) on tissue microarrays. Correlations with clinicopathological parameters were evaluated using Chi-square or Fisher’s exact tests, and prognostic value was assessed by log-rank and multivariate Cox regression analyses. Functional assays, including CCK-8, colony formation, Transwell, and xenograft models, were performed to examine the roles of LAMB3 and its downstream effector. Mechanistic studies involved RNA sequencing (RNA-seq), gain- and loss-of-function experiments, RT-qPCR, RNA immunoprecipitation, and western blotting. Results LAMB3 was significantly upregulated in GC and correlated with aggressive features and poor prognosis. LAMB3 enhanced GC cell proliferation, migration, and invasion. RNA-seq identified sterile alpha motif domain-containing protein 4 A (SAMD4A) as a critical downstream effector. Silencing SAMD4A suppressed, while its restoration rescued, LAMB3-induced malignancy. Mechanistically, LAMB3 activated PI3K-Akt signalling through SAMD4A-mediated degradation of PHLPP2 mRNA. Conclusions This study uncovers a previously unrecognised LAMB3-SAMD4A-PHLPP2 regulatory axis that sustains PI3K-Akt activation and drives GC progression, offering potential prognostic and therapeutic value.

  • Ketohexokinase-A deficiency attenuates the proliferation via reducing β-catenin in gastric cancer cells

    by Gang Ma, Siya Liu, Fenglin Cai, Han Liang, Jingyu Deng, Rupeng Zhang, Mingzhi Cai


  • EGLN3 attenuates gastric cancer cell malignant characteristics by inhibiting JMJD8/NF-κB signalling activation independent of hydroxylase activity

    by Fenglin Cai, Xiuding Yang, Gang Ma, Pengliang Wang, Mengmeng Zhang, Nannan Zhang, Rupeng Zhang, Han Liang, Yongzhan Nie, Cheng Dong, et al.

    Background The expression of Egl-9 family hypoxia-inducible factor 3 (EGLN3) is notably decreased in various malignancies, including gastric cancer (GC). While the predominant focus has been on the hydroxylase activity of EGLN3 for its antitumour effects, recent findings have suggested nonenzymatic roles for EGLN3. Methods This study assessed the clinical significance of EGLN3 expression in GC and explored the connection between EGLN3 DNA promoter methylation and transcriptional silencing. To investigate the effect of EGLN3 on GC cells, a gain-of-function strategy was adopted. RNA sequencing was conducted to identify the key effector molecules and signalling pathways associated with EGLN3. Results EGLN3 expression was significantly reduced in GC tissues, correlating with poorer patient prognosis. EGLN3 hypermethylation disrupts transcriptional equilibrium, contributing to deeper tumour invasion and lymph node metastasis, thus exacerbating GC progression. Conversely, restoration of EGLN3 expression in GC cells substantially inhibited cell proliferation and metastasis. EGLN3 was also found to impede the malignant progression of GC cells by downregulating Jumonji C domain-containing protein 8-mediated activation of the NF-κB pathway, independent of its hydroxylase activity. Conclusions EGLN3 has the potential to hinder the spread of GC cells through a nonenzymatic mechanism, thereby shedding light on the complex nature of GC progression.


  • Open Access

    Evaluation of the prognostic value of negative to positive lymph node ratio in gastric cancer: results from multi-institutional cohorts from western and eastern datasets – Cohort study

    by Xinyu Wang, Pengliang Wang, Wei Wang, Zhe Sun, Zhenning Wang, Rupeng Zhang, Huimian Xu, Zhiwei Zhou, Han Liang, Jingyu Deng

    Introduction: Lymph node (LN) stage is important for prognosis evaluation of gastric cancer (GC) patients. This study aimed to evaluate the prognostic value of the ratio of negative to positive LNs (Rnp) in GC. Methods: The authors evaluated the clinical significance of the Rnp stage in 7660 GC patients from three high-volume institutions in China. Meanwhile, the authors verified the value of the Rnp stage in 11 234 GC patients from the Surveillance, Epidemiology, and End Results (SEER) database. Results: The patients were stratified into different subgroups based on the N stage of the eighth edition of the TNM staging system, the ratio of positive to detected LNs (Rpd) and Rnp. The survival analysis showed clear differences between the three LN stages in both the China and Surveillance, Epidemiology, and End Results cohorts. In univariate and multivariate analyses, the Rnp stage provided smaller Akaike information criterion or Bayesian information criterion values and a larger likelihood ratio χ2 than the N or Rpd stages in both two cohorts. For patients with inadequate examined LNs (<16), the Rnp stage showed better prognostic evaluation performance than the other two stages. In addition, the 5-year disease-specific survival of GC patients showed a slight variation with increasing LNs in the same subgroup classified by the Rnp or Rpd stages compared to the N stage. Conclusions: Along with the higher prognostic value, the Rnp stage has excellent universality with GC patients compared to the N or Rpd stages. Studies with larger sample sizes are needed to predict the prognosis and provide more precise treatment for GC patients.


  • Voltage hysteresis of magnesium anode: Taking magnesium-sulfur battery as an example

    by Ruinan Li, Yaqi Li, Rupeng Zhang, Mengxue He, Yulin Ma, Hua Huo, Pengjian Zuo, Geping Yin


  • Open Access

    Methylation of CpG sites in RNF180 DNA promoter prediction poor survival of gastric cancer

    by Jingyu Deng, Han Liang, Guoguang Ying, Rupeng Zhang, Baogui Wang, Jun Yu, Daiming Fan, Xishan Hao

    RNF 180, a novel tumor suppressor, has been implicated in the carcinogenesis and progress of gastric cancer. At present study, we found that lower expression of RNA180 was specific in gastric cancer tissues, and the inconsistently methylated levels of RNF180 promoter were identified in the gastric cancer tissues. Importantly, we demonstrated that the methylated CpG site count and four hypermethylated CpG sites (-116, -80, +97, and +102) were significantly associated with the survival of 400 gastric cancer patients, respectively. With multivariate survival analyses, we demonstrated that both the methylation of combined CpG (-116, -80, +97, and +102) sites and N stage were the independent indictor of prognosis of gastric cancer patients. Eventually, the methylation of combined CpG (-116, -80, +97, and +102) sites was identified to have smaller AIC value than N stage by mean of AIC calculation with the Cox proportional hazards model. These findings indicated that the quantitative detection of RNF180 promoter methylation had the intensive feasibility for evaluation the prognosis of gastric cancer patients in clinic.